Proteinuria is a late-onset adverse event in patients treated with cabozantinib

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey, Lesley A. Stevens, Christopher H. Schmid et al. · Annals of Internal Medicine · 2009 · 25.7K citations

Pharmacy, Nephrology, Physiology +12

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

Medicine, Oncology, Cancer Pharmacology +12

Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer

Martin Schlumberger, Makoto Tahara, Lori J. Wirth et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Marcia S. Brose, Christopher M. Nutting, Barbara Jarząb et al. · The Lancet · 2014 · 1.6K citations · Full text

Medicine, Endocrinology, Oncology +11

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Samuel A. Wells, Bruce G. Robinson, Robert F. Gagel et al. · Journal of Clinical Oncology · 2011 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +6